



COMMENTARY

Hypoxia-based Stem/Progenitor Cell Therapy: Focus on CXCR4/SDF-1 Axis

Asieh Heirani-Tabasi¹, Shirin Hamedakbari Toosi², Mahdi Mirahmadi¹, Mahmood Raeesolmohaddeseen^{1*}

¹Stem Cells and Regenerative Medicine Research Group, Iranian Academic Center for Education, Culture and Research (ACECR), Khorasan Razavi Branch, Mashhad, Iran

²Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Received 16 November 2016

Accepted 10 October 2017

ABSTRACT

Cell therapy is becoming a promising approach to treat degenerative diseases. Homing of the transplanted cells is one of the continuous challenges being faced by the stem cell biologists. Chemokine receptors are one of the highly studied factors which are known to be crucial in controlling the cell/stem cell migration and targeted homing to the damaged tissues. The expression of chemokine receptors is dependent on a number of transcription factors and HIF-1 α has been considered the crucial molecules controlling cellular migration and homing. Several studies have revealed that hypoxia conditions stabilize the HIF-1 α which upregulate the CXCR4/SDF-1 expression and help in the improvement of tissue regeneration. Here, we review pivotal roles of HIF-1 α /CXCR4/SDF-1 pathway in homing of progenitor/Stem cell which were affected by physical hypoxia as well as various hypoxia-mimicking agents.

Keywords: Cell therapy, HIF-1 α , CXCR4/SDF-1 Axis, Hypoxia-mimicking agents, Therapeutic strategy, Regenerative medicine.

Introduction

Repairing of damaged or injured tissues is raising a major health concern and is one of the current challenges being faced by clinical practitioners. Stem/progenitor cells have been considered as an appropriate therapy for clinical purposes to repair irreversible tissue injuries and enhance tissue regeneration (1). Recently, appealing knowledge of

stem cell therapy has been highly regarded in preclinical and clinical studies. It has been known that throughout the lifespan of individuals, stem cells maintaining their differentiation and proliferative capacity, repair the damaged tissues. For stem cell based regenerative therapies, mesenchymal stem cells (MSCs) are considered as

* Correspondence:

Email: raisy_m@yahoo.com

64

an interesting source of stem cells because of its immunosuppressive property, multilineage potential, differentiation, proliferative and self-renewal capacity (2). Studies have shown that tissue hypoxia may be an essential mechanism governing progenitor and stem cell survival and recruitment to the damaged tissues (3). Hopefully, increasing trend of stem cell therapy in clinic is offering a promising therapy for many patients suffering from degenerative diseases and further strategies to improve the efficacy of stem cell therapy will assure the patients and clinicians trust on cell-based therapeutic approaches. In this commentary, we have focused hypoxia based treatment approaches to enhance the stem cell therapeutic efficacy for improved regeneration.

HIF-1 and its Pivotal Role in Stem Cells Functioning

Oxygen plays a crucial role in the maintenance of stem cell appreciation in terms of cell proliferation and differentiation. It has been determined that hypoxia inducible factor-1 (HIF-1) expression is regulated by oxygen which is responsible to control the expression of various stem cell characteristics genes. Oxygen is required as a necessary condition for culturing of stem cells in laboratory at a concentration of 20% but cellular niche usually required only 2 and 9% for their normal function (4). MSCs maintain their niches and themselves in low O₂ concentration by generating high levels of hypoxia inducible factors (HIFs). HIFs are activated when O₂ concentration falls below 5% and their amount increase in parallel with reduction in oxygenation (3). HIFs is a transcriptional factor that are necessary for cell functions and adaptation in hypoxia condition. HIFs activated when their subunits HIF- α (HIF-1 α , HIF-2 α , and HIF-3 α) interacts with HIF- β subunits (HIF-1 β and HIF-2 β). HIF-1 α subunit has been better known in the activation of some target genes and their mechanisms (5). It has been determined that under normal O₂ concentration, at least there are three different HIF prolyl hydroxylases (PHDs) that hydroxylate the prolyl residues in the HIF-1 α oxygen-dependent degradation domain (ODD) and cause HIF-1 degradation; thereby regulating HIF-1 triggered signalling pathway (6). PHDs exist in three isoforms and catalyzed the degradation by an enzyme is named FIH (factor inhibiting HIF) having asparagine hydroxylase activity. These enzymes are

dioxygenases and start their activity when bind with oxygen or 2-oxoglutarate as their substrates. So, in the hypoxic conditions, there is not enough oxygen and these enzymes (PHDs and FIH) don't find their substrates thus remain inactive. Their inactivity stabilizes and translocates HIF α to nucleus and then it interacts with HIF β and a heterodimer develops. This heterodimer binds to the hypoxia response elements in the regulatory regions on DNA and regulate expression of relevant genes (7). It also has been studied that hypoxia-inducible factor1 α (HIF1 α) is ubiquitinated by an E3-ligase complex to control proteasomal degradation (8).

HIF-1 Protein and the Expression of CXCR4/SDF-1 Axis

CXCR4/SDF-1 axis has been studied by a number of researchers explaining their role in stem cells and cancer cells homing to a specific tissue (9, 10) and this pathway has been described to be critical for regeneration of various damaged tissues (11). HIF-1 through the induction of SDF-1 expression by endothelial cells attracts stem and progenitor cells to the injured sites of tissue. Due to the hypoxic induced temporary condition in stem cells niche, HIF-1 being stabilize and CXCR4⁺ cells start migrating toward damaged tissues (12). In contrary, HIF-1 overexpression is a negative signature in many types of human cancers because HIF-1 via CXCR4/SDF-1 axis enhances cancer cell metastasis (13, 14). Therefore reducing the CXCR4 expression or blocking it by several compounds or strategies is a serious concern in targeted cancer therapy (15). However, high expression of CXCR4 due to hypoxic conditions in various cell types such as monocyte-derived macrophages, monocytes, cancer cells, tumor-associated macrophages, endothelial cells and mesenchymal stem cells is important for degenerative diseases (10, 16, 17). Studies discussing the importance of CXCR4/SDF-1 pathway in cell migration are enlisted in Table 1.

Hypoxia as a Therapeutic Strategy in Regenerative Medicine

Hypoxia which stabilizes the HIF-1 α protein in the later inflammatory phase is involved in, endogenous cell recruitment wound healing, angiogenesis and tissue repair (6).

Table 1. Stem/progenitor cells homing repairs injured tissue by CXCR4/SDF1 pathway.

Stem Cell Type	Site of injury	Ref
BM-MSCs	Myocardial	(18,21)
Cardiac progenitor cells	Myocardial	(22)
Endothelial progenitor cells (EPCs)	Myocardial	(23)
PBMNCs	Myocardial	(24)
BM-MSCs	Renal	(25, 26)
HSCs	Renal	(27)
renal progenitor cells	Renal	(28)
BM-MSCs	Brain infarction	(29)
Ad-MSCs	Brain infarction	(30)
Neural stem cells (NSCs)	central nervous system (CNS)	(31)
Ad-MSCs	Bone marrow	(32)
HSCs	Hepatic	(33, 34)
Liver oval cells	Hepatic	(35)
Ad-MSCs	Diabetes induced Erectile Dysfunction (DED)	(36)

Interestingly, hypoxia based therapies facilitates the angiogenesis and also modifies the metabolism of hypoxic tissues to potentially retain tissue functions normal against any possible ischemic. It has been found that MSCs inhabit in hypoxic niches in the body that provide a undifferentiated states (3). Several studies have demonstrated that hypoxic induction in MSCs leads to stabilize the HIF-1 α and upregulates the CXCR4/SDF-1 which increases angiogenesis and *in vivo* recruitment of MSCs to damaged tissues (37, 38). A number of hypoxia-mimicking agents have been described in Table 2 which are required to stabilize HIF-1 α in stem/progenitor cells for enhanced homing.

Conclusion

Hypoxia has been described as an important cell culturing condition which results in the upregulation of CXCR4 by means of explained HIF pathways (HIF-1 α). Upregulation of CXCR4 enhanced the cell/stem cells homing

towards the injured tissues. Considering this enhanced migration of stem cells, it has been considered that HIF-1 α could be a target molecule in stem cell therapy for clinical applications and improved strategies to increase HIF-1 α activation are required for this near-to-end translational research.

Table 2. Some hypoxia-mimicking agents that stabilized HIF-1 α .

Hypoxia mimicking agent	Mechanism	Stem/progenitor cell	Ref
2,29-dipyridyl	Decreased levels of multiubiquitinated HIF-1 α	HEK-293 (human embryonic kidney)	(39)
Desferoxamine (DFX)	Controlling iron availability (inhibiting PHDs)	BM-MSC	(7, 40)
CoCl₂	Controlling iron availability (inhibiting PHDs)	BM-MSC	(7, 40)
Dimethylglycine (DMOG)	Antagonists of 2-oxoglutarate (inhibiting PHDs)	BM-MSC	(7, 41)
Ciclopirox olamine (CPX)	Induced EPO	Neuroprogenitor cells	(42)
FG-4497	Inhibiting PHDs	Neuroprogenitor cells	(42)
Valproic acid	HIF-1 α upregulation	Mouse Embryonic Stem Cells	(43)

References

1. Chen F-M, Wu L-A, Zhang M, Zhang R, Sun H-H. Homing of endogenous stem/progenitor cells for in situ tissue regeneration: promises, strategies, and translational perspectives. *Biomaterials*. 2011;32(12):3189-209.
2. Heirani-Tabasi A, Hassanzadeh M, Hemmati-Sadeghi S, Shahriyari M, Raeesolmohaddesin M. Mesenchymal Stem Cells; Defining the Future of Regenerative Medicine. *Journal of Genes and Cells*. 2015;1(2):34-9. DOI: 10.15562/gnc.15.
3. Palomäki S, Pietilä M, Laitinen S, Pesälä J, Sormunen R, Lehenkari P, Koivunen P. HIF-1 α is upregulated in human mesenchymal stem cells. *Stem Cells*. 2013;31(9):1902-9.
4. Haque N, Rahman MT, Abu Kasim NH, Alabsi AM. Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy. *The Scientific World Journal*. 2013;2013.
5. Zagórska A, Dulak J. HIF-1: the knowns and unknowns of hypoxia sensing. *Acta Biochimica Polonica*. 2004;51(3):563-85.
6. Nauta TD, van Hinsbergh VW, Koolwijk P. Hypoxic Signaling During Tissue Repair and Regenerative Medicine. *International journal of molecular sciences*. 2014;15(11):19791-815.
7. Silvestre J-S, Smadja DM, Lévy BI. Postischemic revascularization: from cellular and molecular mechanisms to clinical applications. *Physiological Reviews*. 2013;93(4):1743-802.
8. Kanaya K, Kamitani T. pVHL-independent ubiquitination of HIF1 α and its stabilization by cobalt ion. *Biochemical and biophysical research communications*. 2003;306(3):750-5.
9. Mishan MA, Heirani-Tabasi A, Mokhberian N, Hassanzade M, Moghaddam HK, Bahrami AR, Ahmadiankia N. Analysis of Chemokine Receptor Gene Expression in Esophageal Cancer Cells Compared with Breast Cancer with Insights into Metastasis. *Iranian journal of public health*. 2015;44(10):1353.
10. Naderi-Meshkin H, Matin MM, Heirani-Tabasi A, Mirahmadi M, Irfan-Maqsood M, Edalatmanesh MA, Shahriyari M, Ahmadiankia N, Moussavi NS, Bidkhor HR. Injectable hydrogel delivery plus preconditioning of mesenchymal stem cells: exploitation of SDF-1/CXCR4 axis towards enhancing the efficacy of stem cells' homing. *Cell biology international*. 2015.
11. Heirani-Tabasi A, Naderi-Meshkin H. CXCR4: A Potential Chemokine Receptor for Future Regenerative Therapeutic Target. *Journal of Cell and Molecular Research*. 2015;7(2):143-4.
12. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nature medicine*. 2004;10(8):858-64.
13. Ishikawa T, Nakashiro K-I, Klosek SK, Goda H, Hara S, Uchida D, Hamakawa H. Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. *Oncology reports*. 2009;21(3):707-12.
14. Guan G, Zhang Y, Lu Y, Liu L, Shi D, Wen Y, Yang L, Ma Q, Liu T, Zhu X. The HIF-1 α /CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells. *Cancer letters*. 2015;357(1):254-64.
15. Mishan MA, Ahmadiankia N, Matin MM, Heirani-Tabasi A, Shahriyari M, Bidkhor HR, Naderi-Meshkin H, Bahrami AR. Role of Berberine on molecular markers involved in migration of esophageal cancer cells. *Cellular & Molecular Biology*. 2015 20151215;61(8):37-43.
16. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, Nebuloni M, Vago L. Regulation of the chemokine receptor CXCR4 by hypoxia. *The Journal of experimental medicine*. 2003;198(9):1391-402.
17. Naderi-Meshkin H, Bahrami AR, Bidkhor HR, Mirahmadi M, Ahmadiankia N. Strategies to improve homing of mesenchymal stem cells for greater efficacy in stem cell therapy. *Cell biology international*. 2015;39(1):23-34.
18. Takahashi M. Role of the SDF-1/CXCR4 system in myocardial infarction. *Circulation Journal*. 2010;74(3):418-23.
19. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, Liu X, Li Y, Ward CA, Melo LG. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. *Molecular Therapy*. 2008;16(3):571-9.
20. Cheng Z, Liu X, Ou L, Zhou X, Liu Y, Jia X, Zhang J, Li Y, Kong D. Mobilization of mesenchymal stem cells by granulocyte colony-stimulating factor in rats with acute myocardial infarction. *Cardiovascular Drugs and Therapy*. 2008;22(5):363-71.
21. Zhang D, Fan G-C, Zhou X, Zhao T, Pasha Z, Xu M, Zhu Y, Ashraf M, Wang Y. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. *Journal of molecular and cellular cardiology*. 2008;44(2):281-92.
22. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, Sun T, Kishore R, Phillips MI, Losordo DW, Qin G. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. *Circulation research*. 2009;104(10):1209-16.
23. Jian K, Shi Y, Zhang Y, Mao Y, Liu J, Xue F. Time course effect of hypoxia on bone marrow-derived endothelial progenitor cells and their effects on left ventricular function after transplanted into acute myocardial ischemia rat. *European review for medical and pharmacological sciences*. 2015;19(6):1043-54.

24. Wojakowski W, Tendera M, Michałowska A, Majka M, Kucia M, Maślankiewicz K, Wyderka R, Ochała A, Ratajczak MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. *Circulation*. 2004;110(20):3213-20.
25. TÖGel F, Isaac J, Hu Z, Weiss K, Westenfelder C. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. *Kidney international*. 2005;67(5):1772-84.
26. Liu N, Patzak A, Zhang J. CXCR4-overexpressing bone marrow-derived mesenchymal stem cells improve repair of acute kidney injury. *American Journal of Physiology-Renal Physiology*. 2013;305(7):F1064-F73.
27. Lotan D, Sheinberg N, Kopolovic J, Dekel B. Expression of SDF-1/CXCR4 in injured human kidneys. *Pediatric Nephrology*. 2008;23(1):71-7.
28. Mazzinghi B, Ronconi E, Lazzeri E, Sagrinati C, Ballerini L, Angelotti ML, Parente E, Mancina R, Netti GS, Becherucci F. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. *The Journal of experimental medicine*. 2008;205(2):479-90.
29. Wang Y, Deng Y, Zhou G-Q. SDF-1 α /CXCR4-mediated migration of systemically transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. *Brain research*. 2008;1195:104-12.
30. Leu S, Lin Y-C, Yuen C-M, Yen C-H, Kao Y-H, Sun C-K, Yip H-K. Research Adipose-derived mesenchymal stem cells markedly attenuate brain infarct size and improve neurological function in rats. 2010.
31. Imitola J, Raddassi K, Park KI, Mueller F-J, Nieto M, Teng YD, Frenkel D, Li J, Sidman RL, Walsh CA. Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1 α /CXCR4 chemokine receptor 4 pathway. *Proceedings of the National Academy of Sciences*. 2004;101(52):18117-22.
32. Bobis-Wozowicz S, Miekus K, Wybieralska E, Jarocha D, Zawisz A, Madeja Z, Majka M. Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. *Experimental hematology*. 2011;39(6):686-96. e4.
33. Kollet O, Shvitiel S, Chen Y-Q, Suriawinata J, Thung SN, Dabeva MD, Kahn J, Spiegel A, Dar A, Samira S. HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. *Journal of Clinical Investigation*. 2003;112(2):160.
34. Lemoli RM, Catani L, Talarico S, Loggi E, Gramenzi A, Baccarani U, Fogli M, Grazi GL, Aluigi M, Marzocchi G. Mobilization of Bone Marrow-Derived Hematopoietic and Endothelial Stem Cells After Orthotopic Liver Transplantation and Liver Resection. *Stem Cells*. 2006;24(12):2817-25.
35. Hatch HM, Zheng D, Jorgensen ML, Petersen BE. SDF-1 α /CXCR4: a mechanism for hepatic oval cell activation and bone marrow stem cell recruitment to the injured liver of rats. *Cloning & Stem Cells*. 2002;4(4):339-51.
36. Wang X, Liu C, Li S, Xu Y, Chen P, Liu Y, Ding Q, Wahafu W, Hong B, Yang M. Hypoxia Precondition Promotes Adipose-Derived Mesenchymal Stem Cells Based Repair of Diabetic Erectile Dysfunction via Augmenting Angiogenesis and Neuroprotection. *PLoS one*. 2015;10(3).
37. Muscari C, Giordano E, Bonafè F, Govoni M, Pasini A, Guarnieri C. Priming adult stem cells by hypoxic pretreatments for applications in regenerative medicine. *J Biomed Sci*. 2013;20(1):63.
38. van Weel V, Seghers L, de Vries MR, Kuiper EJ, Schlingemann RO, Bajema IM, Lindeman JH, Delisvan Diemen PM, van Hinsbergh VW, van Bockel JH. Expression of vascular endothelial growth factor, stromal cell-derived factor-1, and CXCR4 in human limb muscle with acute and chronic ischemia. *Arteriosclerosis, thrombosis, and vascular biology*. 2007;27(6):1426-32.
39. Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzhig HK, Bühner C. Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. *Biochemical and biophysical research communications*. 2008;372(4):892-7.
40. Liu H, Xue W, Ge G, Luo X, Li Y, Xiang H, Ding X, Tian P, Tian X. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1 α in MSCs. *Biochemical and biophysical research communications*. 2010;401(4):509-15.
41. Liu XB, Wang JA, Ogle ME, Wei L. Prolyl hydroxylase inhibitor dimethylxylglycine enhances mesenchymal stem cell survival. *Journal of cellular biochemistry*. 2009;106(5):903-11.
42. Milosevic J, Adler I, Manaenko A, Schwarz SC, Walkinshaw G, Arend M, Flippin LA, Storch A, Schwarz J. Non-hypoxic stabilization of hypoxia-inducible factor alpha (HIF- α): Relevance in neural progenitor/stem cells. *Neurotoxicity research*. 2009;15(4):367-80.
43. Lee H-J, Kim K-W. Suppression of HIF-1 α by Valproic Acid Sustains Self-Renewal of Mouse Embryonic Stem Cells under Hypoxia In Vitro. *Biomolecules & therapeutics*. 2012;20(3):280.